重症COVID-19患者中识别出不同的免疫表型
法国单中心前瞻性ICU研究纳入96例确诊SARS-CoV-2感染的成人重症患者,在入ICU当天检测大量免疫学变量,行主成分分析和层次聚类。患者被分为三簇:第1簇为「体液免疫缺陷」表型,以B淋巴细胞缺陷为主、相对低丙种球蛋白血症和中等程度炎症;第2簇为「高炎症」表型,细胞因子(IL-6、IL-1β、IL-8、TNF⍺)水平高并伴CD4+和CD8+ T淋巴细胞缺陷;第3簇为「补体依赖」表型,终末补体激活标志物(C3和sC5b-9升高)升高。三簇免疫特征不同且与不同ICU结局相关。作者认为这种免疫异质性支持在不同患者组中靶向不同介质,并可作为患者识别和临床试验入选的基础。
要点
- 法国单中心前瞻性ICU研究纳入96例确诊SARS-CoV-2感染成人重症患者,入ICU当天行免疫学变量检测。
- 层次聚类识别出三簇:第1簇「体液免疫缺陷」表型以B淋巴细胞缺陷为主、相对低丙种球蛋白血症和中等炎症。
- 第2簇「高炎症」表型表现为IL-6、IL-1β、IL-8、TNF⍺水平高,并伴CD4+和CD8+ T淋巴细胞缺陷。
- 第3簇「补体依赖」表型表现为终末补体激活标志物C3和sC5b-9升高。
- 三簇免疫特征不同且与不同ICU结局相关,作者认为这支持在不同患者组中靶向不同介质。
适用人群与场景
- 法国单中心ICU收治的96例确诊SARS-CoV-2感染的成人重症患者,于入ICU当天采集免疫学变量。
研究设计与关键结果
- 单中心前瞻性研究,纳入96例确诊SARS-CoV-2感染的成人重症患者,对入ICU当天检测的大量免疫学变量行主成分分析和层次聚类。
- 第1簇为「体液免疫缺陷」表型:以B淋巴细胞缺陷为主,伴相对低丙种球蛋白血症和中等程度炎症。
- 第2簇为「高炎症」表型:IL-6、IL-1β、IL-8、TNF⍺水平高,伴CD4+和CD8+ T淋巴细胞缺陷。
- 第3簇为「补体依赖」表型:终末补体激活标志物升高,包括C3和sC5b-9升高。
- 三簇具有不同免疫特征,并与不同ICU结局相关。
证据类型、等级与局限
- 证据类型:单中心前瞻性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,表现出细胞因子释放标志、补体激活或B淋巴细胞缺陷的重症COVID-19患者彼此不同,这种免疫学变异性支持在不同患者组中靶向不同介质。
- 作者认为,上述免疫学分型可作为患者识别和临床试验入选的基础。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection causes direct lung damage, overwhelming endothelial activation, and inflammatory reaction, leading to acute respiratory failure and multi-organ dysfunction. Ongoing clinical trials are evaluating targeted therapies to hinder this exaggerated inflammatory response. Critically ill coronavirus disease 2019 (COVID-19) patients have shown heterogeneous severity trajectories, suggesting that response to therapies is likely to vary across patients.
RESEARCH QUESTION: Are critically ill COVID-19 patients biologically and immunologically dissociable based on profiling of currently evaluated therapeutic targets?
STUDY DESIGN AND METHODS: We did a single-center, prospective study in an ICU department in France. Ninety-six critically ill adult patients admitted with a documented SARS-CoV-2 infection were enrolled. We conducted principal components analysis and hierarchical clustering on a vast array of immunologic variables measured on the day of ICU admission.
RESULTS: We found that patients were distributed in three clusters bearing distinct immunologic features and associated with different ICU outcomes. Cluster 1 had a "humoral immunodeficiency" phenotype with predominant B-lymphocyte defect, relative hypogammaglobulinemia, and moderate inflammation. Cluster 2 had a "hyperinflammatory" phenotype, with high cytokine levels (IL-6, IL-1β, IL-8, tumor necrosis factor-alpha [TNF⍺]) associated with CD4+ and CD8+ T-lymphocyte defects. Cluster 3 had a "complement-dependent" phenotype with terminal complement activation markers (elevated C3 and sC5b-9).
INTERPRETATION: Patients with severe COVID-19 exhibiting cytokine release marks, complement activation, or B-lymphocyte defects are distinct from each other. Such immunologic variability argues in favor of targeting different mediators in different groups of patients and could serve as a basis for patient identification and clinical trial eligibility.
参考来源
- Dupont T, Caillat-Zucman S, Fremeaux-Bacchi V, et al. Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients. Chest. 2020. PMID: 33316234. doi:10.1016/j.chest.2020.11.049
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。